Saturday, June 27, 2020 1:37:56 PM
I hope that you are right. Some time ago I estimated that of the approximately 23 unmethylated post 36(+) months survivors, 20 will be Treatment and 3 will be SOC.
However, for the reasons you stated above, I hope that I am wrong and that you are right although even with 20 long living Treatment vs. 3 long living SOC and given the 70% To 30% DCVax-L/SOC numerical patient ratio, DCVax-L would still have a clear edge.
With respect to methylated GBM, I hope that the IDH mutation work will shed some more light on the survival promoting ability of DCVax-L.
If long living (e.g. 3-5 year survivors) SOC patients, have a larger proportion of patients with the methylated GBM carrying the IDH1 mutation than the proportion of such patients found in the Treatment group, the importance of DCVax-L would be even more obvious.
For example if 4 of 7 Post 5 year SOC survivors have a GBM with the IDH1 mutation and 4 of 35 post 5 year Treatment survivors have a GBM carrying the mutation, the positive role of DCVax-L would become more apparent because the long survival of the SOC group seems to be more associated with the mutation's presence. DCVax-L may be important but so is the mutation.
In fact in this example, if we look at post 5 year survivors whose GBM did not carry the mutation, we would end up with 31 Treatment patients and only 3 SOC patients. This would be a ratio of more than 10 to 1 (31 vs. 3) in favor of the long living Treatment patients whereas before exclusion of long livers with the mutation, the ratio of long living Treatment to long living SOC patients was 5:1 (35 vs. 5). If this is correct, even in the absence of the mutation, early DCVax-L treatment would seem to be very efficacious whereas to achieve a prolonged survival of late treated patients, a co factor (IDH1 mutation) would often be required.
Time will tell whether the data concerning the mutation will be used to further highlight the importance of L.
Recent NWBO News
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM